About 9 results found for searched term "STAT3-IN-23" (0.136 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M49685 | STAT3-IN-23 | STAT |
| STAT3-IN-23 (PY*LKTK) is a potent STAT3 inhibitor. | ||
| M7500 | YK 3-237 | Sirtuin |
| YK 3-237 is a boronic acid chalcone analog of combretastatin a4 (CA-4) and a SIRT1 activator that targets mutant p53. YK 3-237 can reduce the acetylation of mutant p53 protein by activating the SIRT1 enzyme, resulting in a significant decrease in the level of mutant p53 protein. YK-3-237 showed antiproliferative activity against tumor cells containing mutant p53 protein. | ||
| M14148 | STAT3-IN-1 | STAT |
| STAT3-IN-1 (compound 7d) is an excellent, selective and orally active STAT3 inhibitor, with IC50 values of 1.82 μM and 2.14 μM in HT29 and MDA-MB 231 cells, respectively. STAT3-IN-1 (compound 7d) induces tumor apoptosis. | ||
| M21510 | Telaglenastat hydrochloride | Others |
| CB-839 hydrochloride | ||
| Telaglenastat (CB-839) hydrochloride is a pioneering (first-in-class), selective, reversible, orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat hydrochloride has IC50 values of 23 nM and 28 nM for endogenous glutaminase in the kidney and brain of mice, respectively. Telaglenastat hydrochloride also induces autophagy and has strong antitumor activity. | ||
| M28423 | Cerivastatin sodium | HMG-CoA Reductase |
| Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect. | ||
| M28490 | Cerivastatin | HMG-CoA Reductase |
| Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin reduces low-density lipoprotein cholesterol levels. Cerivastatin also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect. | ||
| M40707 | Icotrokinra | IL Receptor/Related |
| JNJ-2113; JNJ-77242113; PN-235 | ||
| Icotrokinra (JNJ-77242113, JNJ-2113) is a novel, orally active IL-23R peptide antagonist for studies related to plaque psoriasis. Icotrokinra exhibits high affinity with human IL-23 receptor hIL-23R with a Kd of 7.1 pM. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in PMBCs (IC50=5.6 pM), and inhibits L-23-induced generation of IFNγ and IL-17A in picomolar levels. | ||
| M40998 | Compound 25ap | HDAC |
| Compound 25ap is a potent HDAC/JAK/BRD4 triple inhibitor designed based on the novel multi-targeted HDAC inhibitor Fedratinib, which promotes the hyperacetylation of histones and α-microtubulin, hypophosphorylation of STAT3, and down-regulation of LIFR, MCL-1, and c-Myc in MDA-MB-231 cells, and possesses antitumor activity. | ||
| M55305 | HJC0123 | STAT |
| HJC-0123 | ||
| HJC0123 is a novel STAT3 inhibitor that suppresses the fibrogenic properties of HSCs. HJC0123 reduced the phosphorylation, nuclear translocation, and transcriptional activity of STAT3. HJC0123 treatment resulted in the inhibition of HSCs proliferation at submicromolar concentrations. It decreased the expression of STAT3-regulated proteins, induced cell cycle arrest, promoted apoptosis and downregulated SOCS3. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
